Search for: "Lange v. United States" Results 1 - 20 of 289
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Apr 2025, 12:21 am by Matthieu Dhenne (Dhenne Avocats)
The American Context In the United States, courts grant anti-suit injunctions more freely, though still under strict criteria. [read post]
4 Apr 2025, 12:21 am by Matthieu Dhenne (Dhenne Avocats)
The US Approach In the United States, ASIs are extraordinary but not unheard of. [read post]
This complaint, like the ones prior to it, did not specifically identify the accused products (Huang v. [read post]
Add to this the fact that the United States Patent and Trademark Office never requires the description to be adapted, yet patent enforcement obviously works there as well, and you may arrive at the conclusion that there is certainly no “business case” for the adaptation of a description if the claims are amended. [read post]
23 Sep 2024, 8:02 am by Matthieu Dhenne (Dhenne Avocats)
Teva Santé et al, No. 12/07203), while a few months later the Paris High Court rejected patentability for successive daily dosage units for administering the active ingredient desogestrel, on the grounds that this was a therapeutic method excluded from patentability (Paris High Court, 5 December 2014, Akzo Nobel NV et al. v. [read post]
In this case, Scandit argued that (unlike the 10x Genomics case) proceedings for the recognition and enforcement in the United States of America of a foreign damages award would result in considerable legal costs which, even if successful, would not have to be reimbursed by the debtor. [read post]
Co-authored by Dara Offrede The first Over-the-Counter Continuous Glucose Monitor (CGM) ever cleared in the United Stated by the FDA was launched by Dexcom. [read post]
9 Jul 2024, 11:28 am
Regulatory hegemony becomes important in that context, and hegemony for the purpose of preserving the solidity and position of States within complex clusters of human collectives may be served virtually through regulation platforms that serve as a united front. [read post]
9 Jul 2024, 4:10 am by Hannah Rigby (Bristows)
This follows his earlier judgment in Teva v Novartis ([2022] EWHC 2847 (Pat)). [read post]
25 Jun 2024, 11:18 am by Roberto Rodrigues Pinho (RNA Law)
  Furthermore, the PDP Project proposal must now include information on “intellectual property, exclusivity contracts or commercial agreements, including details of any agreements or restrictions on licensing or 3rd-party access to the technology” (Annex CX, article 8, V). [read post]